What Happens When the Heart 'Forgets' How to Beat?
Imagine this: A 16-year-old healthy boy, active in football, never complained of shortness of breath or palpitations — suddenly collapsed on the field after scoring a winning goal. No warning. No abnormal EKG during routine examination. No known family history. Autopsy showed a structurally normal heart. The only clue? An EKG recorded during a treadmill test — there, at minute 4, his heart beat in a pattern that
should not exist: a QRS wave turning left, then right, repeating — like the heart was arguing with itself. This is
bidirectional ventricular tachycardia, the electrophysiological signature of CPVT.
Why 'Good Stress' Can Be a Silent Killer?
CPVT is not a common heart disorder. It is not caused by artery blockage, valve defects, or muscle weakness. It is a
chemical communication error in cells. Every time the heart beats, calcium ions must be released from internal cell stores — the sarcoplasmic reticulum — through channels called
ryanodine receptors. In CPVT patients, a mutation in the
RYR2 gene (found in about 55–65% of cases) makes these channels overly sensitive. When adrenaline rises — whether from running, fear, or even loud laughter — calcium leaks uncontrollably. The result: heart cells are misinterpreted as needing to beat now, triggering arrhythmia impulses from multiple points simultaneously. This is not just a fast heartbeat — it is an
intracellular coordination confusion that can cause ventricular fibrillation within 90 seconds.
Treadmill Test Is Not for Measuring Stamina — But to Uncover the Genetic Ghost
Most CPVT patients have perfect resting EKGs. No ST depression, no inverted T waves, no prolonged QT. Thus, it passes school screenings, sports exams, and pre-marriage checkups. Diagnosis only appears when the heart
is forced to speak under pressure: an exercise tolerance test with continuous EKG monitoring. Here, arrhythmia begins at 110–130 bpm — far before maximum level. Even more challenging: 15–20% of patients show only
polymorphic VT without a bidirectional pattern, or even
ventricular couplets that seem 'mild' at first glance. Without specific experience, cardiologists can miss the diagnosis — and each delay increases the risk of sudden death by 10–15% per year.
Flecainide: A Drug Initially Banned — Now a Secret Lifesaver
Beta-blockers like nadolol are the frontline treatment for CPVT — but up to 40% of patients still experience breakthrough arrhythmias. That's where flecainide comes in: not as a regular antiarrhythmic, but as a
ryanodine channel stabilizer. A 2012 clinical study (NEJM) proved that flecainide reduced dangerous arrhythmia episodes by 91% when combined with beta-blockers — its unique mechanism: it directly blocks
calcium leak, not just suppressing adrenaline. Irony? Flecainide was once contraindicated in structural heart disease — but in CPVT, the heart has
no structural issues, so flecainide becomes the most precise weapon. Its use requires strict monitoring, but for many families, it's the difference between a child running on the field — or only watching from the bench.
Generation That Doesn't Know They Carry a 'Time Bomb' in Their DNA
CPVT is inherited in an autosomal dominant manner: if one copy of the
RYR2 gene is faulty, the risk of a child inheriting it is 50%. But here lies the hidden tragedy: many carriers never show symptoms — so they don't know to get tested, and don't know their children need genetic screening from age 5. A study in Finland showed that 37% of CPVT diagnoses were made
after a sudden death of a relative, not before. Now, targeted genetic tests (panel
RYR2,
CASQ2,
CALM1) can be done in 10 days, with costs dropping 60% since 2018. However, only 12% of cardiology centers in Southeast Asia include them in family arrhythmia diagnostic algorithms — not because the technology doesn't exist, but because awareness remains hidden behind long terms:
Catecholaminergic Polymorphic Ventricular Tachycardia. A scary name, but the reality is scarier: a perfectly beating heart — until it is driven by legitimate emotions.
Rujukan: Catecholaminergic polymorphic ventricular tachycardia — Wikipedia
Why This Heart Beats in Two Directions When Running — and Why Doctors Don't See It on a Regular EKG?. Behind a seemingly normal pulse lies a rare genetic condition that can trigger a life-threatening arrhythmia with just joy or a 300-meter run. It leaves no trace on a resting EKG — but appears like a ghost when the heart is stressed. More surprisingly: half of the first patients were diagnosed *after* a close relative died suddenly.. What Happens When the Heart 'Forgets' How to Beat?
Imagine this: A 16-year-old healthy boy, active in football, never complained of shortness of breath or palpitations — suddenly collapsed on the field after scoring a winning goal. No warning. No abnormal EKG during routine examination. No known family history. Autopsy showed a structurally normal heart. The only clue? An EKG recorded during a treadmill test — there, at minute 4, his heart beat in a pattern that should not exist : a QRS wave turning left, then right, repeating — like the heart was arguing with itself. This is bidirectional ventricular tachycardia , the electrophysiological signature of CPVT.
Why 'Good Stress' Can Be a Silent Killer?
CPVT is not a common heart disorder. It is not caused by artery blockage, valve defects, or muscle weakness. It is a chemical communication error in cells . Every time the heart beats, calcium ions must be released from internal cell stores — the sarcoplasmic reticulum — through channels called ryanodine receptors . In CPVT patients, a mutation in the RYR2 gene found in about 55–65% of cases makes these channels overly sensitive. When adrenaline rises — whether from running, fear, or even loud laughter — calcium leaks uncontrollably. The result: heart cells are misinterpreted as needing to beat now, triggering arrhythmia impulses from multiple points simultaneously. This is not just a fast heartbeat — it is an intracellular coordination confusion that can cause ventricular fibrillation within 90 seconds.
Treadmill Test Is Not for Measuring Stamina — But to Uncover the Genetic Ghost
Most CPVT patients have perfect resting EKGs. No ST depression, no inverted T waves, no prolonged QT. Thus, it passes school screenings, sports exams, and pre-marriage checkups. Diagnosis only appears when the heart is forced to speak under pressure : an exercise tolerance test with continuous EKG monitoring. Here, arrhythmia begins at 110–130 bpm — far before maximum level. Even more challenging: 15–20% of patients show only polymorphic VT without a bidirectional pattern, or even ventricular couplets that seem 'mild' at first glance. Without specific experience, cardiologists can miss the diagnosis — and each delay increases the risk of sudden death by 10–15% per year.
Flecainide: A Drug Initially Banned — Now a Secret Lifesaver
Beta-blockers like nadolol are the frontline treatment for CPVT — but up to 40% of patients still experience breakthrough arrhythmias. That's where flecainide comes in: not as a regular antiarrhythmic, but as a ryanodine channel stabilizer . A 2012 clinical study NEJM proved that flecainide reduced dangerous arrhythmia episodes by 91% when combined with beta-blockers — its unique mechanism: it directly blocks calcium leak , not just suppressing adrenaline. Irony? Flecainide was once contraindicated in structural heart disease — but in CPVT, the heart has no structural issues , so flecainide becomes the most precise weapon. Its use requires strict monitoring, but for many families, it's the difference between a child running on the field — or only watching from the bench.
Generation That Doesn't Know They Carry a 'Time Bomb' in Their DNA
CPVT is inherited in an autosomal dominant manner: if one copy of the RYR2 gene is faulty, the risk of a child inheriting it is 50%. But here lies the hidden tragedy: many carriers never show symptoms — so they don't know to get tested, and don't know their children need genetic screening from age 5. A study in Finland showed that 37% of CPVT diagnoses were made after a sudden death of a relative , not before. Now, targeted genetic tests panel RYR2 , CASQ2 , CALM1 can be done in 10 days, with costs dropping 60% since 2018. However, only 12% of cardiology centers in Southeast Asia include them in family arrhythmia diagnostic algorithms — not because the technology doesn't exist, but because awareness remains hidden behind long terms: Catecholaminergic Polymorphic Ventricular Tachycardia . A scary name, but the reality is scarier: a perfectly beating heart — until it is driven by legitimate emotions.
Rujukan: Catecholaminergic polymorphic ventricular tachycardia — Wikipedia https://en.wikipedia.org/wiki/Catecholaminergic polymorphic ventricular tachycardia
